NASDAQ:AEON AEON Biopharma 8/12/2026 Earnings Results & Report $0.17 +0.01 (+4.60%) As of 01:59 PM Eastern This is a fair market value price provided by Massive. Learn more. AEON Biopharma was expected to report earnings on August 12, 2026, after market closes. Analysts expected earnings of -$0.2250 per share. Confirmed results have not been posted yet. This page will update with the reported figures, conference call transcript, and earnings documents as they become available. Research:ProfileForecast Earnings Announcement Details Announcement DateAugust 12, 2026TimeAfter Market Closes AEON Biopharma EPS ResultsActual EPSN/AConsensus EPS -$0.2250Beat/MissN/AOne Year Ago EPSN/AAEON Biopharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesSEC FilingCompany Profile AEON Biopharma Earnings FAQ When is AEON Biopharma's next earnings date? AEON Biopharma's next earnings date is estimated for Friday, November 13, 2026. MarketBeat tracks confirmed and estimated earnings dates for AEON Biopharma on the company's earnings history page. AEON Biopharma Earnings HeadlinesAEON Biopharma Submits IND for Comparative Pharmacodynamic Study of ABP-450November 9, 2026 | globenewswire.comAEON Biopharma (AEON) Set to Announce Quarterly Earnings on FridayNovember 6, 2026 | americanbankingnews.comA little-known law has been quietly applied to your savings for years.Fox News reported that under current law, legal title to most stocks and bonds sits with a central institution, Cede and Company, not the individual investor. If a brokerage collapses and customer securities were pledged as collateral, secured creditors can legally come before account holders. Physical gold held in a self-directed IRA is registered directly to you, with no clearinghouse or central institution holding its title.November 13 at 1:00 AM | Monetary Gold (Ad)AEON Biopharma, Inc. details ABP-450 biosimilar strategy and plans Q4’26 IND submissionOctober 23, 2026 | msn.comCertain Options of AEON Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 12-OCT-2026.October 12, 2026 | marketscreener.comMAEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711October 9, 2026 | markets.businessinsider.comSee More AEON Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like AEON Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AEON Biopharma and other key companies, straight to your email. Email Address About AEON BiopharmaAEON Biopharma (NASDAQ:AEON) is a clinical-stage biopharmaceutical company focused on developing botulinum toxin-based therapies for therapeutic, rather than primarily aesthetic, applications. Its lead product candidate, ABP-450, is an investigational botulinum toxin type A complex being studied for the treatment of neurological and other medical conditions. AEON Biopharma has advanced ABP-450 in clinical development for conditions including chronic migraine and cervical dystonia, a disorder involving involuntary neck-muscle contractions. The company has also evaluated additional potential indications for the product. ABP-450 is not an approved treatment for these conditions, and its safety and effectiveness remain subject to clinical testing and regulatory review. The company became publicly traded in 2023 through a business combination with Priveterra Acquisition Corp. AEON Biopharma is based in the United States and operates in collaboration with research, clinical, manufacturing and regulatory partners as it seeks to develop its pipeline. Marc Forth serves as the company’s chief executive officer.View AEON Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCostco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsLightPath Technologies' Record Backlog Highlights a Bigger Defense OpportunityThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid? Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
